How to Best Measure Disease Progression in Adult Spinal Muscular Atrophy Patients: A Clinical and Neurophysiological Study

da Graça FF, Iwabe C, Nucci A, de Rezende TJR, França MC Jr.
Muscle Nerve 2026 Feb 2. doi: 10.1002/mus.70169
This study aimed to identify the most sensitive clinical, patient-reported, and neurophysiological measures to detect short-term disease progression in untreated adult SMA patients. Amongst every clinician-reported outcomes (MFM, HFMSE, RULM) and patient-reported outcomes (MFIS, CMAP, MUNIX), the MFM was the most sensitive to short-term progression and most closely aligned with neurophysiological markers, supporting its use as primary outcome in clinical trials involving adult SMA patients.

Lien PubMed

Articles dans les revues scientifiques

Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: Is the 2-minute walk test an effective alternative to a 6-minute walk test?

Witherspoon JW, Vasavada R, Logaraj RH, Waite M, Collins J, Shieh C, Meilleur K, Bönnemann C, Jain M.Eur J Paediatr Neurol. 2019. 23 (1), 165-170. L'objectif principal de l'étude est d'étudier l'utilité du test de marche de 2 minutes (2MWT) chez des patients atteints...

lire plus